ClinicalTrials.gg
CompletedNCT07032376Updated Sep 25, 2026

A Rapid Clinical Care Pathway to Care for Patients Affected by Chronic Constipation

An interventional study of Survey and Rectal Expulsion Device use in Constipation, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by University of Michigan · Not applicable, Interventional, and Health services research

How we know

Updated Sep 25, 2026Now CompletedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 346 studies in Constipation with a site in United States — 28 open to participants now, 39 under way, 5 of them phase 3. Constipation · United States.

Enrollment
208th of 308
49 · median 73
Started
2025
with 12 others
No phase
96 of 346
16 open now
Registered
326th of 346
by date
Lead sponsor
7 of 346
University of Michigan

Among the 346 studies in Constipation with a site in United States, this one is the 208th largest by enrollment of the 308 interventional ones that give a count, is one of 13 that started in 2025, is one of 96 with no phase, and was the 326th registered.

Constipation

1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.

Browse Constipation studies →

Open to participants now

28 of the 346 studies in Constipation with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 346 studies in Constipation with a site in United States, or all of them as a file.
02

Study summary

This research is studying how the availability of a Food and Drug Administration (FDA)-cleared point-of-care, bedside device bedside device called Rectal Expulsion Device (RED) can be used to evaluate constipation in the participants' routine office visit with the participants' care provider. In this research, participants will be asked to complete a survey prior to the gastroenterology office consultation. Health-related information will be collected for this research study. There are no additional study visits for this research study.

Read the detailed description

This registration is (Implementation Phase) for the registered study "Guideline to Implementation: A Rapid Clinical Care Pathway to Care for Patients Affected by Chronic Constipation" (Observational Phase) NCT06352827.

03

Conditions studied

  • Constipation

Browse trials for

Keywords

  • Questionnaires
  • Gastroenterology care
  • Rectal Expulsion Device (RED)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participant has Chronic constipation as a main symptom

Exclusion criteria

Exclusion Criteria Participants:

  • Participant has taken narcotic pain medication in the past 30 days
  • Participant has been scheduled for a test called an anorectal manometry in the past 12 months
  • Participant has been scheduled to see a pelvic floor physical therapist in the past 12 months
  • Participant is pregnant
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Chronic constipation

    Participants will complete surveys and may or may not have the Rectal Expulsion Device (FDA 510k approved) used during clinic visit.

    Behavioral: Survey · Behavioral: Rectal Expulsion Device use

Interventions

  • BehavioralSurvey

    All participants will complete a baseline survey and have medical information collected.

  • BehavioralRectal Expulsion Device use

    During the participant's clinic visit for constipation, the Rectal Expulsion Device will be available for the gastroenterology care provider to use if the decision is made to use this during the clinic visit. In addition, the care provider will have access to the RED brochure and the Michigan Chart (MICHART) Our Practice Advisory (OPA) - a decision support tool in MiChart to support care navigation using RED.

06

What researchers measure

Primary outcomes

  1. Percentage of encounters in which anorectal physiology testing is ordered or performed at the baseline routine-care gastroenterology office appointment

    Fidelity to ordering pelvic floor diagnostics

    Time frame: Day 1 (Baseline = initial appointment after consent)]

  2. Percentage of encounters in which pelvic floor physical therapy is ordered at the baseline routine-care gastroenterology office appointment

    Fidelity to ordering pelvic floor treatment

    Time frame: Day 1 (Baseline = initial appointment after consent)]

07

Study locations

1 site
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Sep 2026, 12 months.

Of 246 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 12 months is below that.

Counting every sponsor, half of 317 studies reached it within 14 months; a quarter within 6 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Feb 2027 → Sep 2026 and completion Feb 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Jun 24, 2025
StartActual
Aug 20, 2025
Primary completionActual
Sep 4, 2026was Feb 2027
CompletionActual
Sep 4, 2026was Feb 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Sep 25, 2026
Primary completion
Feb 2027→Sep 4, 2026 (actual)
Sep 25, 2026
Study completion
Feb 2027→Sep 4, 2026 (actual)
Sep 25, 2026
Enrollment
109 (estimated)→49 (actual)
Sep 25, 2026
Documents
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Enrolling by invitation→Completed
    Documents Informed consent form ↗ posted
    Primary completion Feb 2027→Sep 4, 2026 (now actual)
    Study completion Feb 2027→Sep 4, 2026 (now actual)
    Enrollment 109 (estimated)→49 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07032376
Responsible party
Eric Shah (Associate Professor of Internal Medicine, University of Michigan) — Principal investigator
First posted
Jun 24, 2025
Start date
Aug 20, 2025
Primary completion
Sep 4, 2026
Completion
Sep 4, 2026
Last update
Sep 25, 2026

Study contacts

Eric Shah, MD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion